Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep;71(9):1926-1928.
doi: 10.1136/gutjnl-2021-326237. Epub 2021 Nov 24.

Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD

Rosanna Cannatelli  1 , Francesca Ferretti  2 , Stefania Carmagnola  2 , Irene Maria Bambina Bergna  2 , Maria Camilla Monico  2 , Giovanni Maconi  2 , Sandro Ardizzone  2
Affiliations
Comment

Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD

Rosanna Cannatelli et al. Gut. 2022 Sep.
No abstract available

Keywords: COVID-19; adverse drug reactions; inflammatory bowel disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

  • Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
    Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, McGovern DP, Mehta SJ, Murray CD, Patel KV, Pollok RC, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Kennedy NA, et al. Gut. 2021 May;70(5):865-875. doi: 10.1136/gutjnl-2021-324388. Epub 2021 Mar 22. Gut. 2021. PMID: 33753421
  • Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb CA, Macdonald J, Mehta S, Pollok RC, Raine T, Smith PJ, Verma AM, Jochum S, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Kennedy NA, et al. Gut. 2021 Oct;70(10):1884-1893. doi: 10.1136/gutjnl-2021-324789. Epub 2021 Apr 26. Gut. 2021. PMID: 33903149

Substances

LinkOut - more resources